RenalNext analyzes 19 genes (listed above). 18 genes (excluding EPCAM) are evaluated by next generation sequencing (NGS) or Sanger sequencing of all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. In addition, sequencing of the promoter region is performed for the following genes: PTEN (c.-1300 to c.-745), MLH1 (c.-337 to c.-194), and MSH2 (c.-318 to c.-65). For MITF, only the status of the c.952G>A (p.E318K) alteration is analyzed and reported. The inversion of coding exons 1-7 of the MSH2 gene is detected by NGS and confirmed by PCR and agarose gel electrophoresis. Testing to be considered for Early-onset kidney cancer patients who are <46 years of age, >2 family members on same side of the family with kidney cancer OR >3 family members on the same side of family with kidney and other cancers
Renal Cell Carcinoma
BAP1 (BRCA1 Associated Protein 1), CHEK2 (Checkpoint kinase 2), EPCAM (Epithelial cell adhesion molecule), FLCN (Folliculin), MET (MET proto-oncogene, receptor tyrosine kinase), MITF (Melanocyte Inducing Transcription Factor)
See More ...
Next-Generation Sequencing (NGS)